Computational Methods for Drug Repurposing
This detailed book explores techniques commonly used for research into drug repurposing, a well-known strategy to find alternative indications for drugs which have already undergone toxicology and pharma-kinetic studies but have failed later stages during
- PDF / 13,899,928 Bytes
- 331 Pages / 504.63 x 737.01 pts Page_size
- 52 Downloads / 241 Views
Quentin Vanhaelen Editor
Computational Methods for Drug Repurposing
METHODS
IN
MOLECULAR BIOLOGY
Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For further volumes: http://www.springer.com/series/7651
Computational Methods for Drug Repurposing Edited by
Quentin Vanhaelen Insilico Medicine, Inc., Rockville, MD, USA
Editor Quentin Vanhaelen Insilico Medicine, Inc. Rockville, MD, USA
ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-8954-6 ISBN 978-1-4939-8955-3 (eBook) https://doi.org/10.1007/978-1-4939-8955-3 Library of Congress Control Number: 2018962410 © Springer Science+Business Media, LLC, part of Springer Nature 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Humana Press imprint is published by the registered company Springer Science+Business Media, LLC, part of Springer Nature. The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.
Preface It is known that despite large R&D resources and expenses, the conventional drug discovery process has become increasingly time-consuming and elicits a relatively high attrition rate. With the current social and demographic trends, this results in an important disparity between the high R&D expenses, reduced number of new drugs, and unmet medical needs. To address these issues, the pharmaceutical sector continuously innovates to implement alternative approaches in order to optimize key steps of the drug discovery pipeline, essentially by focusing on a more accurate identification of promising candidates. Among them, drug repurposing is a well-known strategy to find alternative indications for drugs that have already undergone toxicology and pharma-kinetic studies but have failed in later stages during the development. Nevertheless, identifying new
Data Loading...
